Business ❯ Healthcare ❯ Biotechnology

Drug Development

Clinical Trials Colorectal Cancer Clinical Testing Antibody-Drug Conjugates Targeted Protein Degradation Vaccine Approval Acquisitions FDA Approval Autoimmune Diseases CGT9486 Lab Equipment Renal Diseases Cushing's Syndrome Treatments Viking Therapeutics Bruton's Tyrosine Kinase Inhibitors Immunology Zymeworks Inc. Chronic Diseases Market Trends GLP-1 Weight Loss Drugs Small-Molecule Therapies

OrbiMed Sells 860,123 Enliven Shares in Roughly $39 Million Transaction

A partial reduction that leaves OrbiMed holding roughly 6.6 million shares could shift investor views of Enliven's Phase 1 drug pipeline.

Roche and Nurix Strike $700M Deal to Co‑Develop Oral BTK Degrader Bexobrutideg

Kailera Leaps 62% in Nasdaq Debut After $625 Million IPO

AnaptysBio Seeks to Toss Tesaro Anticipatory‑Breach Claim in Jemperli Royalty Dispute

Amgen Buys Oxford Spinout Dark Blue Therapeutics for Up to $840 Million

Novo Nordisk Files for 7.2 mg Wegovy Dose After Stronger Weight-Loss Results

Biogen Licenses Vanqua’s Preclinical C5aR1 Drug in Deal Worth Up to $1.06 Billion